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The term ‘‘new onset diabetes after transplantation (NODAT)’’
refers to new incidence of diabetes mellitus after solid organ
transplantation. NODAT is among the metabolic complications
after liver transplantation that has been reported to be associated
with negative impact on patient and graft survival. Several risk
factors have been proposed but the precise pathogenesis has
not been well demonstrated. It should be noted that not all
patients, even with all of the risk factors, develop NODAT. This
implies the role of genetic predisposition in the pathogenesis of
NODAT.
I read with great interest the recently published paper by Ling
et al. showing the association between donor and recipient tran-
scription factor 7-like 2 (TCF7L2) gene polymorphisms with the
development of NODAT after liver transplantation [1]. In multi-
variate analysis, they showed that donor and recipient
rs290487 single nucleotide polymorphism (SNP) (C-allele) in
TCF7L2 gene was signiﬁcantly associated with the incidence of
NODAT after liver transplantation. Other independent risk factors
for NODAT were advanced recipient age and higher blood tacrol-
imus levels at 1 month after liver transplantation. Their results
are interesting with respect to the identiﬁcation of a genetic sus-
ceptibility for NODAT in liver transplant recipients.
Several previous studies have conﬁrmed that TCF7L2 is a
major susceptibility gene for type 2 diabetes in different popula-
tions [2]. The product of this gene binds to beta-catenin (b-cat)
and forms a bipartite transcription factor known as TCF-b-cat,
which is an important effector of Wnt signaling [3]. It has been
reported that TCF7L2 depletion in human pancreatic islets
resulted in a signiﬁcant increase in b-cell apoptosis and decrease
in insulin secretion [3]. Expression of TCF7L2 and glucagon like
peptide-1 was decreased in human islets from patients with type
2 diabetes mellitus [4]. Therefore, TCF7L2 gene plays an impor-
tant role in b-cell function and proliferation in type 2 diabetes.
Recently published studies have reported TCF7L2 gene polymor-
phism in patients with latent autoimmune diabetes of adult
(LADA) [5].
LADA is classically categorized as a form of type 1 diabetes
although it exhibits some clinical and laboratory features of both
type 1 and 2 diabetes, resulting in the use of the term ‘‘type 1.5
diabetes’’ by some authors [6]. Patients with LADA are older than
35 years at onset of diabetes and their disease is initially con-
trolled with diet and oral hypoglycemic agents. These clinical fea-
tures are similar to patients with type 2 diabetes, but they will
require insulin therapy in a shorter period of time than that of
type 2 diabetes patients. On the other hand, patients with LADA
are non-obese, ketosis prone patients with unstable blood glu-
cose level and presence of islet autoantibodies in the blood [6].
These features are similar to those of patients with type 1
diabetes. Anti-glutamic acid decarboxylase (GAD) and anti-islet-
cell cytoplasm (ICA) are more common than other types of
autoantibodies in these patients [7]. Furthermore, insulin resis-
tance in LADA patients is less common than type 2 diabetes
and is similar to type 1 diabetes [6].Journal of Hepatology 2013Several features of NODAT are comparable with LADA.
Therefore, NODAT can be categorized in this subgroup of
patients with diabetes. As outlined in the present study, obes-
ity was not an independent risk factor for NODAT. In fact, body
mass index (BMI) at the ﬁrst and third months after liver
transplantation was not different between patients with
NODAT and patients without NODAT. Therefore, it seems that
the effect of higher BMI in the development of NODAT, as
reported in previous studies, may be delayed to the period
after the 6th month of transplantation. Patients with NODAT
are prone to ketosis and there are several reports of presenta-
tion of NODAT with keto-acidosis [8]. Patients with NODAT can
be treated initially with oral hypoglycemic agents such as
patients with LADA. Although several studies have reported
the role of insulin resistance and impaired insulin response
in the development of NODAT, it has been reported that b-cell
dysfunction rather than insulin resistance is involved in the
pathogenesis of NODAT [9]. Additional important evidence is
obtained from a cross sectional study that reported ICA positiv-
ity, but not other autoantibodies, in patients after liver trans-
plantation on tacrolimus therapy. All of these patients had
post-transplant diabetes at the time of examination or devel-
oped diabetes in their follow-up [10]. This pattern of autoanti-
body positivity is also very similar to LADA patients.
In this well-designed and well-performed study, TCF7L2 gene
polymorphism was associated with incidence of NODAT in liver
transplant recipients. TCF7L2 gene is not only a predisposing gene
for type 2 diabetes but also for LADA. Investigating the associa-
tion between islet autoantibodies, markers of insulin resistance
and blood tacrolimus level with TCF7L2 polymorphism in patients
with NODAT was some valuable information that the study did
not provide. Taking this evidence into account and considering
the results of the current study, NODAT should not be simply cat-
egorized as type 2 diabetes and may fall into the LADA category.vol. 58 j 1053–1061 1059
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To the Editor:
We would like to thank Dr. Eshraghian for his interest in and
insightful comments on our article. Both of us believe that
genetic factor involves in the pathogenesis of new onset diabe-
tes after transplantation (NODAT). Dr. Eshraghian summarized
the association between TCF7L2 gene and diabetes, and
explained the underlying mechanism by the role of TCF7L2 gene
in human pancreatic islets. Here, we would like to make an
additional explanation that TCF7L2 gene also plays a crucial role
in hepatic glucose metabolism by interacting with multiple
gluconeogenic genes and regulating glucose intolerance in the
liver [1,2]. TCF7L2 is important for insulin secretion and also
critical for hepatic glucose production and hepatic insulin
sensitivity. Therefore, in our study, both donor and recipient
TCF7L2 genetic variants were associated with the onset of
NODAT, possibly via the effects on donor liver glucose metabo-
lism and recipient islets.
Dr. Eshraghian presented comprehensive data on a very inter-
esting possible link between NODAT and latent autoimmune dia-
betes in adults (LADA), which would help better understand the
etiology of NODAT. However, there is similarity but also diversity
in the etiology and pathophysiology of NODATs after different
organ transplantation [3]. He pointed out that b-cell dysfunction
rather than insulin resistance is the main cause of NODAT after
kidney transplantation [4], while in liver transplantation, insulin
resistance, especially liver insulin resistance, is considered to
make a great contribution to NODAT [5]. Compared to other
transplanted solid organs (e.g., kidney, heart, lung), the liver
has the particularity that it is the principal organ for carbohy-
drate, protein, lipid and drug metabolism. Therefore, we hypoth-
esized that donors’ phenotype and genotype may affect
metabolic status in liver transplant recipients, and the primary
purpose of our study was to investigate the role of donor liver
in the development of post-liver transplantation complications.
In our previous study, donor CYP3A5 gene polymorphisms were
associated with the metabolism of tacrolimus in liver transplan-
tation [6], and donor rs290487 genetic variant in TCF7L2 gene
increased NODAT risk after liver transplantation [7]. In our most
recent study, we showed that donor’s genotype could even con-
tribute to intrahepatic recurrence of hepatocellular carcinoma
after liver transplantation (unpublished data). Taken together,
these ﬁndings provide evidence that donor liver does have a great
inﬂuence on the post-liver transplant complications, and open a
door to evaluate the respective roles of donor and recipient or
even their cross-talk in the outcome after liver transplantation.
LADA is distinguished from type 2 diabetes by the presence of
islet autoantibodies [8]. With great interest, we learn the possible
link between NODAT and LADA. We should admit that NODAT
shares some similarities with LADA in clinical presentation.
However, it is still too early to say whether NODAT could be
categorized into this subgroup because the etiologies of both
NODAT and LADA are unclear. According to the LADA China study
[8], glutamic acid decarboxylase antibody (GADA) positive phe-
notypic type 2 diabetes (<1 year post diagnosis, without insulin
therapy for >6 months, agedP30 years) was considered as LADA.
Circulating islet autoantibodies are essential in the diagnosis of
LADA. Up to now, the most important evidence to prove the asso-
ciation between NODAT and LADA is from Lohmann et al. [9], as
mentioned by Dr. Eshraghian. In a cohort of 58 patients, they
found that islet cell autoantibodies-positive patients with tacrol-
imus treatment were more prone to have NODAT after liver
transplantation [9]. Other evidence is from genetics research
indicating that both diseases were related to TCF7L2 gene poly-
morphisms [7,10]. However, other important points for the diag-
nosis of LADA, such as time to insulin dependence, age and body
mass index (BMI), are unspeciﬁc and anthropogenic in NODAT.
For instance, perioperative or in-hospital hyperglycemia is rou-
tinely treated with insulin so that time for an insulin intervention
is dependent on local clinicians; patient age at adult liver trans-
plantation is usually beyond 35 years; BMI is always low in
chronic consumption such as cirrhosis, but can increase in cirrho-
sis with massive ascites and edema. Therefore, further well-
designed and large sample studies are needed to evaluate the
LADA-associated characters in NODAT and to explore the possible
correlation. Studying the association between TCF7L2 gene and
clinical parameters (e.g., islet cell autoantibodies, insulin resis-
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